S SERVIER
Updates & Highlights
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at SERVIER?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recent18 Year-Old Payton’s Powerful Journey of ALL – Servier Pharmaceuticals
18 Year-Old Payton’s Powerful Journey of ALL – Servier Pharmaceuticals
Oncodaily · 2 days ago
Every Month Matters When Facing a Cancer Diagnosis – Servier Pharmaceuticals
Every Month Matters When Facing a Cancer Diagnosis – Servier Pharmaceuticals
Oncodaily · 3 days ago
Servier and Cure51 launch a research partnership
Servier and Cure51 launch a research partnership
Servier · 5 days ago
Servier and Cure51 partner to identify new glioblastoma drug targets
Servier and Cure51 partner to identify new glioblastoma drug targets
manufacturingchemist.com · 6 days ago
Owkin licenses AI scientist, patient data to Servier for oncology research
Owkin licenses AI scientist, patient data to Servier for oncology research
MobiHealthNews · 6 days ago
Read News and Stories about Servier Partnering Day
Read News and Stories about Servier Partnering Day
Oncodaily · 6 days ago
Servier Partnering Day: Connecting Pharma, Biotech, and Academia for New Opportunities
Servier Partnering Day: Connecting Pharma, Biotech, and Academia for New Opportunities
Oncodaily · 7 days ago
Servier Pharmaceuticals Puts Acute Lymphoblastic Leukemia in Focus
Servier Pharmaceuticals Puts Acute Lymphoblastic Leukemia in Focus
Oncodaily · 8 days ago
Blood Cancer Awareness Month Highlights Evolving Treatment and Research – Servier
Blood Cancer Awareness Month Highlights Evolving Treatment and Research – Servier
Oncodaily · 8 days ago
Inspiring Story Audrey Who Was Diagnosed With Acute Myeloid Leukemia Last October - Servier
Inspiring Story Audrey Who Was Diagnosed With Acute Myeloid Leukemia Last October - Servier
Oncodaily · 8 days ago
Blood Cancer Awareness Month: Advancing Hope for Patients and Families - Servier Pharmaceuticals
Blood Cancer Awareness Month: Advancing Hope for Patients and Families - Servier Pharmaceuticals
Oncodaily · 9 days ago
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
HPCwire · 9 days ago
Owkin Licenses K Pro AI Scientist And Multimodal Patient Data To Servier For Oncology Research
Owkin Licenses K Pro AI Scientist And Multimodal Patient Data To Servier For Oncology Research
Pulse 2.0 · 9 days ago
Servier Becomes Latest Company to License Owkin’s K Pro AI Scientist
Servier Becomes Latest Company to License Owkin’s K Pro AI Scientist
Contract Pharma · 9 days ago
Owkin Licenses K Pro, Patient Data to Servier for Oncology Research
Owkin Licenses K Pro, Patient Data to Servier for Oncology Research
Unite.AI · 9 days ago
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Business Wire · 9 days ago
Owkin, Servier ink oncology R&D deal to guide discovery and trial design
Owkin, Servier ink oncology R&D deal to guide discovery and trial design
Fierce Biotech · 9 days ago
IDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma
IDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma
AllSci · 11 days ago
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
PR Newswire · 11 days ago
Servier expands its Golden Ticket program to China
Servier expands its Golden Ticket program to China
Servier · 13 days ago